Exposure-adjusted incidence rates of serious adverse events 8.5 versus 11.2 per 100 patient-years for anifrolumab versus placebo
Breakthrough Infections in Lupus Patients Down With COVID Booster
Sixty-four percent of those with breakthrough COVID-19 had received booster compared with 82 percent of those without breakthrough infection
ACR: Lupus Patients Can Have Low Immune Response to COVID-19 Vaccines
However, overall disease activity does not appear to change after vaccination
ACR: COVID-19 Vaccine Not Tied to Severe Rheumatic Disease Flares
Seropositivity lags after vaccination in those with rheumatic diseases but improves after second dose
Two-Thirds of Lupus Patients Likely to Take COVID-19 Vaccine
However, national survey uncovered racial differences in uptake, safety concerns